Good afternoon, and welcome to the Q3 2021 Knowles Corporation Earnings Conference Call. My name is Emma, and I will be your conference operator today. At this time, I would like to welcome everyone to the conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by one on your telephone keypad. If you would like to withdraw your question, again, press star one. With that said, here with opening remarks is Knowles' Vice President of Investor Relations, Mike Knapp. Please go ahead. Thanks, Emma, and welcome to our Q3 2021 Earnings Call. I'm Mike Knapp, and presenting with me on the call today are Jeffrey Niew, our President and CEO, and John Anderson, our Senior Vice President and CFO. Our call today will include remarks about future expectations, plans, and prospects for Knowles, which constitute forward-looking statements for purposes of the safe harbor provisions under applicable federal securities laws. Forward-looking statements in this call will include comments about demand for company products, anticipated trends in company sales, expenses, and profits, and involve a number of risks and uncertainties that could cause actual results to differ materially from current expectations. The company urges investors to review the risks and uncertainties in the company's SEC filings, including, but not limited to the annual report on Form 10-K for the fiscal year ended December 31st, 2020, periodic reports filed from time to time with the SEC, and the risks and uncertainties identified in today's earnings release. All forward-looking statements are made as of the date of this call, and Knowles disclaims any duty to update such statements except as required by law. In addition, pursuant to Regulation G, any non-GAAP financial measures referenced during today's conference call can be found in our press release posted on our website at knowles.com and in our current report on Form 8-K filed with the SEC, including a reconciliation to the most directly comparable GAAP measures. All references on this call will be on a non-GAAP continuing operations basis, unless otherwise indicated. We've made selected financial information available on the webcast slides, which can be found in the IR section of our website. With that, let me turn the call over to Jeff, who will provide some details on our results. Jeff. Thanks, Mike, and thanks to all of you for joining us today. For Q3, we reported revenue of $233 million above the midpoint of our guidance and up 13% from the year-ago period, driven by strong demand across our Audio and Precision Devices segments. Gross margins improved to 41.8%, near the high end of our guidance range, and our earnings per share was $0.45 above the high end of our expectations. In Audio, revenue was up 8% from the year-ago period as Hearing Health sales increased on strong end market demand, and MEMS microphone sales grew, driven primarily by IoT. Precision Devices delivered record revenues again in Q3, up 35% from the year-ago period, driven by improved demand across a broad range of end markets we serve and an acquisition we completed in Q2. We also delivered cash from operations of $56 million. Overall, another strong quarter that demonstrates the benefit of our investment in differentiated products to increase revenue across a diverse set of growing end markets, driving gross margins higher and delivering strong earnings and cash flow. Let me now spend some time on detailing the trends we are seeing by the end markets in each one of our business segments. In Audio, we saw broad-based improvement year-over-year in MEMS microphone sales, despite experiencing supply constraints. Hearing Health sales also increased from the year-ago period on strong end market demand. As we look forward, we believe recently proposed rules from the FDA on over-the-counter hearing aids, if adopted, will make it easier for people with mild hearing loss to have access to technology to improve quality of life. We expect this new channel to bolster our growth in Hearing Health over the years to come. We are increasing our capacity to service our traditional hearing aid market and the opportunities for the over-the-counter and true wireless markets. Moving on to Precision Devices. Sales reached record levels again in Q3, with significantly improved gross margins as demand from medtech, industrial, defense, and electric vehicle markets drove strong year-over-year improvement. We continue to develop advanced solutions for mission-critical applications that rely on our high-performance capacitors and RF filters, which is yielding solid results. In high-performance capacitors, the medtech market drove a significant portion of the year-over-year growth as demand improved for our high-reliability products used in implantable devices and MRI machines. We are also beginning to see a broadening of our customer base in Asia and Europe as high-voltage EV platforms begin to go to production. In our filters, our product continues to see strong demand from defense customers in North America and Europe for communications and radar solutions. We are also beginning to see a number of new design opportunities in 5G mm wave telecom, and we secured several prototype orders for small cells and repeater equipment. For the third consecutive quarter, we saw record bookings in PD across a wide array of products, giving me confidence we can grow Precision Devices revenue by greater than 15% this year, with the bulk of the growth being driven by organic initiatives. In a moment, John will discuss the Q3 results and the Q4 guide in more detail, but our revenue growth is currently being held back by a number of short-term issues that have recently been in the headlines, which include extended lead times and capacity constraints on semiconductors, and more recently, power disruptions in China, as well as some lingering COVID uncertainty. For the past several years, our strategy has been to focus our R&D investment, capacity expansions, and acquisitions in products for growing markets that value our differentiated solutions. This is paying dividends today as gross margin continues to expand, driving increased operating income and cash flows. As these headwinds start to dissipate, we expect the impact of our strategy to be even more pronounced on our financial results. Our team has delivered three strong quarters so far this year. I believe our leadership positions across the markets we serve, and our strategy to deliver high-value solutions to a diverse set of growing end markets, positions us well for the rest of 2020, 2021, and beyond. With that, I'll turn it over to John to expand on our financial results and provide the guidance for the fourth quarter. John? Thanks, Jeff. We reported third quarter revenues of $233 million, up 13% from the year ago period, driven by increased shipments in both the Audio and Precision Devices segments. Audio revenues of $178 million were up 8% due to higher demand for MEMS microphones across mobile and non-mobile end markets and stronger hearing aid sales. Precision Devices delivered record revenues of $55 million, up 35% year-over-year, as a result of organic growth of 21% and an acquisition completed in the second quarter of 2021. Third quarter gross profit margins were 41.8%, near the high end of our guidance range and up more than 500 basis points versus the same period a year ago. Audio segment gross margins improved more than 450 basis points, driven by productivity gains, higher factory capacity utilization, and favorable product and customer mix. In the Precision Devices segment, gross margins were more than 600 basis points above prior year levels due to productivity gains, improved factory utilization, favorable inventory reserve adjustments, and an acquisition partially offset by higher precious metals cost. R&D expense in the quarter was $20 million, up slightly from the year ago period, but lower than expected due to the timing of new hires. SG&A expenses were $27 million, in line with our guidance range, and up $1 million from the prior year, driven primarily by higher incentive compensation cost and an acquisition partially offset by lower legal expense. For the quarter, adjusted EBIT margin was 22.6%, above the high end of our guidance range, and up more than eight percentage points from the same period a year ago, driven by higher gross profit margins, improved operating leverage, and favorable FX impacts. EPS was $0.45, above the high end of our guidance range, and up $0.21 from the prior year. Further information, including a detailed reconciliation of GAAP to non-GAAP results, is provided in the financial tables of today's press release and can also be found on our website at knowles.com. Now I'll turn to our balance sheet and cash flow. Cash and cash equivalents totaled $140 million at the end of Q3. Cash generated by operations in the quarter was $56 million, above the high end of our guidance due to higher EBITDA and lower than expected net working capital. Capital spending was $12 million in the quarter. Given our existing cash position and our expectations that we will continue to generate significant free cash flow in the future, we will settle the principal amount of the convertible notes which mature next month in cash. Moving to the fourth quarter, we expect total company revenue to be between $230 million and $235 million, down 4% at the midpoint versus the same period a year ago. Revenue from the Audio segment is expected to be down approximately 14% from Q4 2020, driven by timing of customer product launches and supply chain constraints, resulting in reduced MEMS microphone shipments, partially offset by higher Hearing Health revenues. Precision Devices revenue is expected to be up more than 40% versus the prior year, driven by strong organic growth in the defense, medtech, and industrial end markets, and the acquisition completed in the second quarter of this year. We estimate total company gross margins for the fourth quarter of 40%-42%, up 300 basis points from the year ago period, driven by higher capacity utilization, favorable product mix, and the acquisition completed in Q2. Our gross margin expansion through the first three quarters of 2021 demonstrates the execution of our strategy to deliver high-value differentiated solutions to our end markets. We expect total company gross profit margins will reach approximately 41% for full year 2021, a record high and approximately 200 basis points above 2019 levels. R&D expense in Q4 is expected to be between $19 million-$21 million, flat with prior year levels. We're projecting selling and administrative expense to be between $27 million-$29 million, up $1 million from the year ago period, driven by higher incentive compensation cost and the impact of the acquisition completed earlier this year. Adjusted EBIT margin for the quarter is expected to be approximately 21%. EPS is expected to be within a range of $0.43-$0.45 per share. This assumes weighted average outstanding shares during the quarter of 95.6 million on a fully diluted basis. Despite the near-term supply chain challenges which are impacting revenue, our actions to improve gross margins coupled with our discipline over operating expense spending is resulting in an expected increase in full year EPS of nearly 40% above 2019 levels. We're forecasting an effective tax rate of 8%-12% for the quarter. This range includes a discrete tax benefit related to the filing of our 2020 federal tax return. Going forward, due to the potential expiration of a tax holiday at the end of 2021. Our future expected effective tax rate may increase to 14%-18%. We're expecting cash generated by operations in Q4 to be between $45 million and $55 million, and capital spending to be approximately $20 million. Please refer to our press release and to our Form 8-K filed today with the SEC for a GAAP to non-GAAP reconciliation. I'll now turn the call back over to Jeff for closing remarks, and then we'll move to the Q&A portion of the call. Jeff? Thanks, John. We are increasingly confident about our near and longer-term prospects as our strategy to deliver high-value, differentiated solutions to a diverse set of growing end markets is allowing us to expand gross margins while driving operating income and producing strong cash flow. We will continue to drive shareholder value through investment in high gross margin products, accretive acquisitions, and stock buybacks. Before we move to the Q&A, I would like to announce we are planning on hosting an investor call in late November to provide an update on our growth opportunities and our capital allocation strategy, as well as provide new midterm financial targets. More detail will follow in the near future, and we are excited about the opportunity to share our plans for revenue growth and gross margin expansion and what it means for operating margins and cash flow. With that, I'll turn it over to open for Q&A. At this time, I would like to remind everyone in order to ask a question, press star, then the number one on your telephone keypad. We'll pause for just a moment to compile the Q&A roster. Your first question comes from the line of Bob Labick with CJS Securities. Your line is now open. Good afternoon. Congratulations on a nice quarter. Thanks, Bob. Thanks Bob. I wanted to dig in on a few things you mentioned on, you know, earlier. As it relates to the supply chain, can you give us, you know, kind of a sense of how much of it is, you know, international labor, chip shortage, and roughly how big a revenue hit it is? And then, you know, going from there, how long do you think this, you know, will impact you and your customers, looking ahead? Yeah. First I just, you know, make a comment. You know, I think we are being cautious in our guidance that we're providing. You know, I think, you know. You know, right now we're kind of in the midst of this and, you know, with or without, you know, going through a ton of detail, you know, I would probably estimate in 2021, this is probably $15 million+. In the back half. In the back half of the year. Yeah. You know, some of it's in Q3, majority in Q4. I think that's probably about a number, $15 million+. You know, it's hard to say. You know, again, we're obviously working with our suppliers. I think it's mainly semiconductor. I wouldn't call at this point that we're having major labor shortages or issues like that. We have had some downtime on power in China, which had some impact for us in early Q4, late Q3. Some of that seems to have passed right now, but you know, we'd like to see how that continues through the rest of the quarter. Again, we're being cautious. I would sit there and say right now, I kind of view this, you know, these things are gonna linger around into Q1 for sure, maybe, you know, possibly into Q2, and that's when we start to see these things start to clear up. Now, you know, again, I'm not gonna call this exactly, Bob, but that's kind of what we see right now. Got it. Okay, great. No, that's great and helpful color. You mentioned the Hearing Health of the ear, you know, over-the-counter market. Can you maybe give us a sense of, you know, where the FDA, you know, is, how long this could take to be an opportunity for you, and how big the market opportunity might, you know, be for you? Yeah. I'm not gonna speculate on what the government's gonna do. I'm just gonna talk about how we see this market though, Bob, and how we see it is, it's incremental. Here's why we see it this way, and I think I've talked about this on other calls. You know, if you look at that pyramid that we've talked about of hearing loss, profound hearing loss, significant hearing loss, mild hearing loss, the most underserved portion of that is mild hearing loss, and that's also the largest portion of people who have hearing loss, and this is where we think this is gonna be targeted. We have some customers who've, you know, introduced over-the-counter products already into the marketplace and are being sold today. I think there's a couple points I would make is, number one is, at least preliminarily, people who are buying the very early days over-the-counter hearing aids, the average age is much younger than the traditional hearing aid channel to the tune of 10-15 years younger. I think the positive of that is for us, number one, is it brings somebody into the idea of, you know, improvement of quality of life significantly earlier in their life, and that allows for us to have, you know, again, multiple cycles of technology and buys of hearing aids over time. It increases the TAM. It really increases the TAM, both 'cause you're bringing new mild hearing loss people in, but also at a younger age. To speculate on how big this market is, you know, I would probably say that, you know, the overall hearing aid market is roughly 15 million units a year. That's the rough size of the market. I would be, you know, probably thinking, you know, next two-three years, this could be a couple million, 2 million-3 million hearing aids a year. We're very encouraged, last piece, about the idea here that if you look at people who have introduced products to the market, they're not focused on cost, they're focused on performance, and that's a really important point for us, right? We want, you know, people who are focused on performance, right? Because first of all, you don't wanna turn people off with their first experience with a hearing aid by buying something cheap, but also because they value our high value products, you know, whether it be in microphones or in our speakers and receivers. Okay, great. Thanks. Then one last one, and I'll get back in queue. Obviously showing a lot of success in the Precision Devices market and both organically, but through acquisitions you've made in the past too. Can you just give us a sense of the M&A environment out there and if there's, you know, opportunities for you with your, you know, pristine balance sheet now to continue to make some acquisitions in Precision Devices? Yeah. I would say that, you know, the funnel is pretty active. We're very active in M&A area. On the reverse side, I would also say the valuations are quite high. You know, I think from my perspective, it's really important, especially at the type of valuations that we're extremely disciplined about what we're gonna do. You know, I think the acquisition that we did earlier this year has been very successful. The three or four other ones that we did since 2017 have all been successful. We wanna keep up that track record. I think the point I would just say is I'm hopeful that we can get some more acquisitions done over the next, you know, 18 months. Just keep that in mind is that, you know, we are trying to be very disciplined about valuation. Got it. Super. All right. Thanks very much. No problem. Your next question comes from the line of Suji Desilva with Roth Capital. Your line is now open. Hi, Jeff. Hi, John. Congrats on the cash generation and the margin execution here. First thing, maybe on the gross margin, since we're there, what are some of the key factors that are driving the strength? I know you have an event coming up to talk about it, but you know, how sustainable is some of the improvement that you've seen? Good question, Suji. You know, in terms of the audio segment, you know, year-over-year, our gross profit margin improvement is really driven by, to a great extent, mix. Specifically a higher proportion of MEMS microphones shipped for non-mobile applications, also growth in the Hearing Health business. Those are both probably the key drivers. Obviously, we're also running our factories at pretty high levels, you know, 90%+ in terms of capacity utilization. I'd say those are probably the main things. We've also been really successful. You know, we're paying higher price per chips. We've been pretty successful at passing those costs on to our customers. With PD, I think it's similar. Mix is really helping, you know, higher proportion of sales going into higher margin medical and defense applications. Then they've really made, you know, a lot of progress on productivity gains within the factories and really optimal lot sizes, reducing scrap and excess in inventory. It's some blocking and tackling, but it's also some really favorable mix. Yeah. Let me just maybe a little bit broader top line. He's given you the detail, like what's going on, like, right now. You know, again, I think as we talked about this, Suji, over the last couple quarters, the three, four quarters, about where we're investing our R&D resources, where we're investing our CapEx, and we're really trying to focus this in on non-commoditized products, right? What's happening is, as we get more of these products into the marketplace, we spend more money in these areas, you're seeing that in terms of the mix. Just to finish up too, Suji, you know, with respect to, you know, I noted in my script that I'm confident that we'll be at or maybe even slightly above 41% for full year 2021. At this investor call we have later in the quarter, we'll talk about opportunities to expand gross margins further. Okay. Look forward to that, John. A couple questions on the supply constraint. In terms of the lead customer and the mics, I'm wondering if the ordering patterns would kind of have some of the ordering that might happen in the fourth quarter push out to the first quarter, if that's not the way this would play out, given the constraints. Any color there would be helpful. Yeah. I'm not gonna comment specific to one customer, but here's what I'd say relative to that. You know, we all know that the timing of the launch is slightly off from last year. You know, it was delayed. You know, there was COVID-related issues. This year, it was earlier. I think it was more like a traditional pattern. I think let me just speak generally and again, not to a specific customer, but, you know, I would say, you know, first, you know, the $15 million that I kinda said earlier that we could have shipped more is what we are being constrained by. I'm not trying to quantify here what our customers are being constrained by. You know, there's clearly, you know, some constraints out there in certain applications with certain products, you know, across the customer base, but that's not even quantified into the 15 million. The 15 million I'm for the back half is really what we think we could have shipped more if we could have gotten or built more microphones. Okay. That's helpful clarification. Then lastly, on PD, the bookings visibility very strong there. I'm wondering if any component of that is related to supply constraints and customers trying to cover their supply needs or, you know, how much of that versus the growth in the bookings that's really driving that. I would say the vast majority of the growth we don't see it that way. Let me just kind of frame this out here. You know, we kind of have an industrial distribution kind of piece of business. That one piece within PD, there could be some or more ordering than we normally would see. When you start thinking about defense or aerospace, the majority of this is all custom product they're ordering for. We don't really have a supply constraint in that area. The life sciences stuff, I don't see that. I don't think that there's a lot of custom there. Automotive, again, custom. I don't really see this, at least in our minds, that the vast majority of the growth. I would say this industrial/distribution business, which, you know, ends up being about 15% of the business, that area could be, you know, expanding at a faster rate maybe than it actually. The demand is there. The rest of the business I think is pretty solid. Okay. Thanks for the color, Jeff. Your next question comes from the line of Tristan Gerra with Baird. Your line is open. Hi. Good afternoon. You talked about passing higher costs to customers, and could that provide a fairly different pricing outlook for next year? In other words, you know, could pricing be up next year as a result, and should we view this as a top-line contributor? Well, I guess what I would say is that I think it's a little too early to make that call yet. I think we're gonna have to see after as we get through, and I always pick this point in time. We gotta get through the holiday season here in the U.S. and then Chinese New Year, and then see where things stand. I mean, you know, in spite of, you know, everything that's going on, you know, China's still weak for us. I mean, it's still weak for us. We'll see how this kind of develops as we get closer to Chinese New Year. It's still, you know, quite weak. You know, I would say, you know, when we talk a lot about MEMS mics and the pricing environment and passing on costs, but the pricing environment, you know, in my mind, in both PD and Hearing Health has been reasonably favorable. I mean, so, you know, I think overall, you know, as you know, again, I guess this goes back to what we said a few questions ago, is that the more we focus on non-commoditized portions of our market, the more positive the pricing will become, and gross margin will be better. Okay. Great. Any update on the balanced armature speaker and where you stand in terms of finalizing that automated factory in the Philippines? I'm glad I got that question, Tristan. Yeah. The team is there. I just saw actually a video with the first products coming off the line. You know, obviously this is not fully qualified yet, but we're expecting to be shipping to customers this quarter. That's the expectation right now, is that in Q4 we'll start shipping off the automated line. Yeah. If you think about it, you know, as I said it before, you know, it's been touch and go for so long. You know, I mean, I thank the teams that have gone there. By the way, just, you know, the teams that maybe there's some of them are listening, they're in the Philippines. They had to quarantine for seven days when they got there before they could go into the factory, which I know is a total pain in the neck, and so I appreciate the teams willing to go there and do that. But we expect that, you know, as design wins start to ramp, we probably won't see full utilization of the capacity, you know, in the first half of next year. It'll start ramping, you know, to closer to full utilization in the back half of 2022. Great. Very useful. Thank you. Thanks, Tristan. Your next question comes from the line of Christopher Rolland with Susquehanna International Group. Your line is now open. Hi. Good afternoon. This is actually Daoxuan Zhang on for Chris. I just wanna follow up on the gross margin question. Obviously, a great progression here, but I'm curious how much more upside the utilization can bring to the table. You already said +90% right now. Yeah. Also- Yeah. Go ahead. Yeah. The Hearing Health part as well seems like it's already recovered quite a bit. What are some of the other drivers that could help you to get to that 42% target? Yeah. As I mentioned, we're gonna give a little more clarity and color on future gross margin expansion. You know, there's a few levers that we'll talk about. You know, mix is one of them, higher growth in, I'll call it the Hearing Health, the Precision Devices, the non-mobile MEMS mic business. That's one. But we'll elaborate a little more on those drivers. Let me make a couple comments. I think number one, new products will obviously across all of our businesses will drive that, number one. Number two is I think we've talked pretty extensively, you know, in our business we're really not intent on adding capacity to maintain commoditized products of selling. I think, you know, that keeps going back to, you know, obviously there's mix within what products we're selling, but there's also the fact that, you know, we kind of see is that lower gross margin MEMS business kind of falls off the bottom, and we've talked about things like die sales to be able to like service those types of markets. We do think there is some opportunity yet for gross margin expansion. As John said, we'll go through those details on the investor call we'll have in late November. Sounds good. On the inventory side, seems like for the past couple quarters you've been building internal inventory, but this quarter it was down by 24 days. Would you say you're in a comfortable range right now, and should we interpret this as strong demand overall, or is it more supply constraints kicking in? I think it's a little bit of both. I mean, we do have definitely supply constraints on certain product categories where, you know, if we could build more, we would, and we're, I would say, closer to hand-to-mouth on inventory on certain products. On the reverse I think, you know, inventory being down, you know, there is beyond the supply constraints, there's the issue of this normal seasonality where I think we go through with, you know, in Q1, Q2, we bring raw materials in, and Q2 into Q3, we build the product. We have our strongest quarter typically, you know, either in Q3 or in Q4, which draws inventory down. This is following kind of the normal path that we saw. We are having constraints that allow us not to build as much as we'd like. One other point I'd add is that that's kind of unique to this year is we're transitioning in our MEMS microphone business, transitioning to 8-in, so we're carrying a little extra inventory. I'd expect that to go down kind of mid-2022. Yeah, to further a point, I would sit there and say, you know, at this point, you know, I think we talked about utilization. Because of supply constraints, we are not running in our microphone business at full capacity right now. We are not, like, running at full capacity right now. Sounds good. Thank you very much. At this time, there are no further questions. Mr. Knapp, I turn the call back over to you. Great. Thanks, Emma, and thanks to everyone for joining us today. As always, we appreciate your interest in Knowles. We're also gonna be participating in the Roth Conference on November 18th and a Wells Fargo conference on December 2nd. We hope to speak with you then, or on our next earnings call, and we'll also have more information out on our investor update, later in November. Thanks, and goodbye. This concludes today's conference call. You may now disconnect.